Lenalidomide plus rituximab produces durable responses in mantle cell lymphoma patients

(H. Lee Moffitt Cancer Center & Research Institute) New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. The results from the multicenter phase 2 study were published in the Nov. 5 issue of The New England Journal of Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news